Precision Medicine is Exploding: How Will You Scale to Keep Up?

  • September 09, 2020
  • 1:00 PM – 2:00 PM ET
  • Online
about

The cost of precision medicine is growing at 12-15% annually, and many agree that no smaller cohort of health insurance membership drives a higher financial risk than precision oncology. This means the time is now for health insurance providers to address outdated decision-making and reimbursement practices that threaten patient accessibility and the speed of progress in this area of health care.

Two precision oncology experts share insights into these challenges. They will discuss why information overload is leading to inconsistent treatment decisions in precision oncology, why traditional prior authorization can’t scale to meet the challenges, and where health insurance providers can look for true innovation that increases patient access and creates a path to value-based care in precision medicine.

Our presenters will share a live demonstration of the Trapelo™ platform – a first-of-its-kind clinical-decision-support solution that infuses prior authorization into the clinical workflow in real time to truly enable next-generation oncology management.

Attendees will learn about:

  • The size of the precision medicine challenge and the exposure it presents for health insurance providers
  • How to efficiently ensure that every member receives access to appropriate testing and treatment
  • How to ensure doctors are keeping up with the explosion of complexity—and particularly new biomarkers, tests, and therapies—without slowing down workflow
  • Why traditional prior authorization for next-generation oncology care is falling short
  • What solutions currently exist that enable real-time alignment in decision making to streamline PA and reduce unnecessary delays, denials, and appeals
  • How health care providers and payers can access real-time information to ensure the appropriate use of precision medicine

Speakers


Lee N. Newcomer, MD, MHA
Oncologist and Principal
Lee N Newcomer Consulting

Dr. Newcomer has dedicated his career to creating new approaches to make cancer care more effective and affordable, and to create novel approaches for improved care of cancer patients.

The majority of his career was spent with UnitedHealth Group, where from 1991 to 2001 he was their Chief Medical Officer and built the company’s medical management programs. He returned in 2006 to lead an initiative combining clinical, financial and program management experts to focus on cancer care, creating the first commercial cancer database combining clinical and claims data.

Prior to his work at UnitedHealth Group Dr. Newcomer practiced medical oncology for nine years in Minneapolis and Tulsa, Oklahoma. He also served as the Medical Director for Cigna Healthcare, in Kansas City and he was a founding executive of Vivius, a consumer-directed venture that allowed consumers to create their own personalized health plans.

Dr. Newcomer received his MD from the University Of Nebraska College of Medicine and a Masters of Health Administration from the University of Wisconsin at Madison. His clinical training included an internal medicine residency at the University of Nebraska Medical Center and a medical oncology fellowship at the Yale University School of Medicine.


Clynt Taylor
CEO
Trapelo Health

Clynt Taylor is CEO at Trapelo Health, a healthcare technology company on a mission to address the challenges of transitioning to the next generation of oncology care. He brings more than 20 years of experience in healthcare technology. Under his leadership, Trapelo Health launched the first precision medicine platform used by oncologists, labs, payers, and pharma, and founded the Precision Medicine Podcast, a media platform that brings together industry leaders to help accelerate the effective use of precision medicine.

" "